Low levels of neutralizing antibodies against SARS-CoV-2 KP.3.1.1 and XEC in serum from seniors in May 2024
New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that are either widely distributed or on the rise globally, in sera from a cohort of seniors aged 68 - 82 years from April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, supporting the recommendation of an updated covid-19 vaccine booster in this age group.
immunology↗